"Guidance was needed for which tests to use for screening and monitoring this particular disease," said lead author Sindhu R. Johnson, MD, PhD. The full manuscript will be published by early 2024.
The novel agent targets CD40 ligand and showed promising results in a two-stage, phase 2 clinical trial, particularly for patients with notable symptom burden but limited systemic organ involvement.
/PRNewswire/ A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled.